2024 Stock itci - See the latest Intra-Cellular Therapies Inc stock price (NASDAQ:ITCI), related news, valuation, dividends and more to help you make your investing decisions.

 
seekingalpha.com - August 12 at 10:29 AM. GW&K Investment Management LLC Purchases 302,685 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) marketbeat.com - August 11 at 7:34 PM. Barclays PLC Boosts Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) marketbeat.com - August 8 at 6:11 AM.. Stock itci

When it comes to purchasing a new vehicle, finding the perfect car that meets all your requirements can be a daunting task. If you have your heart set on a Genesis GV70, you’ll want to ensure that you find the best one available in stock.TimesSquare Capital highlighted stocks like Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) in its Q3 2022 investor letter. Headquartered in New York, New York, Intra-Cellular Therapies, Inc. (NASDAQ ...home / stock / itci / itci news. RSS . ITCI ITCI Quote ITCI Short ITCI News ITCI Articles ITCI Message Board. September, 25 2019 07:30 AM ... NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) today announced the successful completion of the second dose cohort (single dose of 30 mg administered …Nov 20, 2023 · Shares of ITCI responded in kind, rallying 16% in the subsequent trading session and ultimately 40% higher to an all-time high of $67.05 in June 2023, suggesting peak sales of $1.75 billion to $2. ... Intra-Cellular Therapies Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ITCI updated stock price target summary.Get the latest stock price for Intra-Cellular Therapies Inc. (ITCI:US), plus the latest news, recent trades, charting, insider activity, ...If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...0001193125-20-135603.txt : 20200507 0001193125-20-135603.hdr.sgml : 20200507 20200507073227 ACCESSION NUMBER: 0001193125-20-135603 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENTsdominick. Introduction. Intra-Cellular Therapies (NASDAQ:ITCI), a pioneering biotech firm, is dedicated to the creation and market introduction of novel small molecule therapies, which are ...Intra-Cellular Therapies (ITCI) Stock Forecast, Price Targets ...Dec 1, 2023 · According to 8 analysts, the average rating for ITCI stock is "Strong Buy." The 12-month stock price forecast is $78.5, which is an increase of 24.92% from the latest price. Price Target Referenced Symbols. Shares of Intra-Cellular Therapies Inc. ITCI, +3.26% jumped about 15% in premarket trading on Tuesday after the company said its experimental treatment for major depressive ...The stock of Intra-Cellular Therapies Inc (ITCI) has gone up by 5.10% for the week, with a -1.20% drop in the past month and a -13.62% drop in the past quarter. The volatility ratio for the week is 5.20%, and the volatility levels for the past 30 days are 3.88% for ITCI. The simple moving average for the last 20 days is -0.20% for ITCI stock ...Nov 24, 2023 · Stock analysis for Intra-Cellular Therapies Inc (ITCI:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. The past 20 months have been good for growth stocks, to say the least. In that time, the S&P 500 just about doubled, while the NASDAQ has done even better, gaining 125%. Corporate earnings ...When picking the best stocks under $10 to buy, it's important to identify fundamentally strong and non-speculative stocks. These are fundamentally strong and non-speculative stocks that are under $10 Since the meme stock euphoria in 2020, i...View the basic ITCI option chain and compare options of Intra-Cellular Therapies, Inc. on Yahoo Finance.Headquartered in Chelmsford, Massachusetts, Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is a sample exploration and management solutions provider for the life science market. On November 23, 2022 ...Intra-Cellular Therapies ( NASDAQ: ITCI) stock traded much higher recently after it had obtained FDA approval for its drug CAPLYTA (lumateperone) for the treatment of adults with bipolar ...Nov 7, 2023 · by Zacks Equity Research Published on November 07,2023. The mean of analysts' price targets for Intra-Cellular (ITCI) points to a 41.2% upside in the stock. While this highly sought-after metric ... Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up Zacks - Wed Mar 29, 11:27AM CDT . Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. Stock surges 16% following the news.A stock is considered to be oversold if the RSI reading falls below 30. In trading on Monday, shares of Intra-Cellular Therapies Inc (Symbol: ITCI) entered into oversold territory, hitting an RSI ...Join Our Free Stock Market Newsletter: StockMarket.com is the #1 resource for all things Stocks. Sign up today for Free!ITCI has received 7 recent reviews, and they all concur – this is a stock to buy, making the Strong Buy consensus view unanimous. The shares are priced at $50.8 and the $62.71 average price ...Are you tired of spending endless hours searching for high-quality stock photos only to discover that they come with a hefty price tag? Look no further. In this article, we will explore the best sources for high-quality really free stock ph...A. The latest price target for Intra-Cellular Therapies ( NASDAQ: ITCI) was reported by RBC Capital on Friday, November 3, 2023. The analyst firm set a price target for 76.00 expecting ITCI to ...Intra-Cellular Therapies ( NASDAQ: ITCI) stock traded much higher recently after it had obtained FDA approval for its drug CAPLYTA (lumateperone) for the treatment of adults with bipolar ...May 2, 2023 · ITCI 4.98%. 58. See ITCI Report. Overall market sentiment has been high on Intra-Cellular Therapies Inc ( ITCI) stock lately. ITCI receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator. Intra-Cellular Therapies Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ITCI! 0001193125-20-214163.txt : 20200810 0001193125-20-214163.hdr.sgml : 20200810 20200810081722 ACCESSION NUMBER: 0001193125-20-214163 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENTIntra-Cellular Therapies (ITCI) Stock Forecast, Price Targets ...The average price recommended by analysts for Intra-Cellular Therapies Inc (ITCI) is $77.54, which is $16.26 above the current market price. The public float for ITCI is 93.65M and currently, short sellers hold a 3.65% of that float. On December 01, 2023, ITCI’s average trading volume was 845.52K shares. Top 5 EV Tech Stocks to Buy for 2023.Briefing From The Editor -- ITCI Stock. Now trading at a price of $49.82, Intra-Cellular Therapies has moved 0.1% so far today. Intra-Cellular Therapies returned gains of 9.0% last year, with its stock price reaching a high of $67.05 and a low of $42.01. Over the same period, the stock underperformed the S&P 500 index by -4.0%.ITCI - Intra-Cellular Therapies Inc Stock Price Quote - NASDAQ | Morningstar Intra-Cellular Therapies Inc ITCI Morningstar Rating | Rating as of Sep 7, 2023 Quote Chart Stock Analysis News...Find the latest dividend history for Intra-Cellular Therapies Inc. Common Stock (ITCI) at Nasdaq.com.May 4, 2023 · Intra-Cellular: Q1 Earnings Snapshot. NEW YORK (AP) — NEW YORK (AP) — Intra-Cellular Therapies Inc. (ITCI) on Thursday reported a loss of $44.1 million in its first quarter. The New York-based company said it had a loss of 46 cents per share. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by ... Intra-Cellular Therapies, Inc. (ITCI) Stock Price, Quote & News - Stock Analysis NASDAQ: ITCI · IEX Real-Time Price · USD -0.01 (-0.02%) Nov 15, 2023, 4:00 …NEW YORK, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, …Intra-Cellular Therapies Inc. Common Stock (ITCI) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. Despite the negative momentum in the past three months at -12.40%, the 6 and 9-month momentum are positive at +19.58% and +14.86% respectively, contrasting slightly with the stock's minor decline ...Real stock prices are not the same as the last traded stock price. Real stock prices are adjustments to closing stock prices. The adjustments are used in a variety of ways, including dividends, the range of prices and the closing price of t...Insider Sell: Sharon Mates Sells 100,000 Shares of Intra-Cellular Therapies Inc. On September 19, 2023, Sharon Mates, Chairman, President & CEO of Intra-Cellular Therapies Inc (NASDAQ:ITCI), sold ...As of April 23, 2023, the average one-year price target for Intra-Cellular Therapies is 77.93. The forecasts range from a low of 56.56 to a high of $102.90. The average price target represents an ...Nov 23, 2023 · Shares of Intra-Cellular Therapies (ITCI Quick Quote ITCI - Free Report) have gained 22.4% over the past four weeks to close the last trading session at $59.26, but there could still be a solid ... 000156751412-312023Q3false13600015675142023-01-012023-09-3000015675142023-10-31xbrli:shares00015675142023-09 …Nov 7, 2023 · by Zacks Equity Research Published on November 07,2023. The mean of analysts' price targets for Intra-Cellular (ITCI) points to a 41.2% upside in the stock. While this highly sought-after metric ... NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the Goldman Sachs 44th Annual Global Healthcare Conference on Monday, …Current. -$0.35. 1 Month Ago. -$0.41. 3 Months Ago. -$0.41. Intra-Cellular Therapies Inc. analyst estimates, including ITCI earnings per share estimates and analyst recommendations.Have the markets turned the corner? Maybe not – but maybe so, at least for the short term. Despite rising inflation in the States, and Russia’s continuing war against Ukraine, high prices for ...ITCI stock rallied 2.2% Friday. Inspire Medical Systems ( INSP ) posted a weekly gain despite three losing days, gaining 3.8% Friday. INSP shares formed a handle and flirted with the 277.28 buy ...View the basic ITCI option chain and compare options of Intra-Cellular Therapies, Inc. on Yahoo Finance.Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up Zacks - Wed Mar 29, 11:27AM CDT . Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. Stock surges 16% following the news.ITCI stock rallied 2.2% Friday. Inspire Medical Systems ( INSP ) posted a weekly gain despite three losing days, gaining 3.8% Friday. INSP shares formed a handle and flirted with the 277.28 buy ...04:20 PM ET 03/28/2023. Intra-Cellular Therapies ( ITCI) said Tuesday that its depression treatment succeeded in a key study, and ITCI stock broke definitively above its 200-day line for the first ...Intra-Cellular Therapies Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ITCI updated stock price target summary.Discover historical prices for ITCI stock on Yahoo Finance. View daily, weekly or monthly format back to when Intra-Cellular Therapies, Inc. stock was issued. Nov 20, 2023 · Shares of ITCI responded in kind, rallying 16% in the subsequent trading session and ultimately 40% higher to an all-time high of $67.05 in June 2023, suggesting peak sales of $1.75 billion to $2. ... GuruFocus Research November 2, 2023 at 10:17 AM · 2 min read Intra-Cellular Therapies Inc ( NASDAQ:ITCI) reported Q3 2023 total revenues of $126.2 …NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the 2023 Cantor Fitzgerald Global Healthcare Conference on Wednesday, …Dec 1, 2023 · According to 8 analysts, the average rating for ITCI stock is "Strong Buy." The 12-month stock price forecast is $78.5, which is an increase of 24.92% from the latest price. Price Target ITCI, -14836.0 shares, $-823694.72, 2023-08-31, N-PORT. No recent transactions ... Stock Lookup. Enter stock name: use * for wildcard.ITCI - place your bets With a huge upcoming catalyst - CAPLYTA PDUFA due December 17th, 2021, it will make or break this stock - with an approval from the FDA, I expect pt of around 57, with possibility to hit all-time high within a year from CAPLYTA launch.52 Week High. $67.05. 52 Week Low. $42.01. Data Provided by Refinitiv. Minimum 15 minutes delayed. The Investor Relations website contains information about Intra-Cellular Therapies Inc.'s business for stockholders, potential investors, and financial analysts. Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.Current. -$0.35. 1 Month Ago. -$0.41. 3 Months Ago. -$0.41. Intra-Cellular Therapies Inc. analyst estimates, including ITCI earnings per share estimates and analyst recommendations.Apr 26, 2017 · ITCI - place your bets With a huge upcoming catalyst - CAPLYTA PDUFA due December 17th, 2021, it will make or break this stock - with an approval from the FDA, I expect pt of around 57, with possibility to hit all-time high within a year from CAPLYTA launch. Get up to 10 years of daily historical stock prices & volumes. The "Close/Last" is the “adjust consolidated close price”. Data provided by Edgar Online. The net and percent change in the quote ...ITCI - place your bets With a huge upcoming catalyst - CAPLYTA PDUFA due December 17th, 2021, it will make or break this stock - with an approval from the FDA, I expect pt of around 57, with possibility to hit all-time high within a year from CAPLYTA launch.Nov 28, 2023 · Nov. 08. CI. RBC Trims Price Target on Intra-Cellular Therapies to $76 From $77, Keeps Outperform Rating. Nov. 03. MT. Earnings Flash (ITCI) INTRA-CELLULAR THERAPIES Reports Q3 Revenue $126.2M. Nov. 02. MT. Transcript : Intra-Cellular Therapies, Inc., Q3 2023 Earnings Call, Nov 02, 2023. 0001193125-20-288507.txt : 20201109 0001193125-20-288507.hdr.sgml : 20201109 20201109074552 ACCESSION NUMBER: 0001193125-20-288507 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENTIntra-Cellular Therapies (ITCI) Jefferies analyst Andrew Tsai maintained a Buy rating on Intra-Cellular Therapies on October 6 and set a price target of $95.00 . The company’s shares closed last ...As of April 23, 2023, the average one-year price target for Intra-Cellular Therapies is 77.93. The forecasts range from a low of 56.56 to a high of $102.90. The average price target represents an ...Nov. 08. CI. RBC Trims Price Target on Intra-Cellular Therapies to $76 From $77, Keeps Outperform Rating. Nov. 03. MT. Earnings Flash (ITCI) INTRA-CELLULAR THERAPIES Reports Q3 Revenue $126.2M. Nov. 02. MT. Transcript : Intra-Cellular Therapies, Inc., Q3 2023 Earnings Call, Nov 02, 2023.At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.What is Intra-Cellular Therapies Inc (ITCI)'s stock price today? The current price of ITCI is $59.42. The 52 week high of ITCI is $67.05 and 52 week low is $42.01. When is next earnings date of Intra-Cellular Therapies Inc (ITCI)?Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools. Identify stocks that meet your criteria using seven unique stock screeners.Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.Mar 1, 2023 · Intra-Cellular (ITCI) delivered earnings and revenue surprises of 27.42% and 5.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. Stock surges 16% following the news.The mean of analysts' price targets for Intra-Cellular (ITCI) points to a 33% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong …Intra-Cellular Therapies, Inc. (ITCI) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Follow. 2W 10W 9M. 62.84 +1.47 (+2.40%) At close: 04:00PM EST. 60.44 -2.40 (-3.82%) After hours:...Shares of Intra-Cellular Therapies (ITCI) have gained 18.4% over the past four weeks to close the last trading session at $52.87, but there could still be a solid upside left in the stock if short ...2 thg 11, 2023 ... ... stock report on ITCI at https://www.zacks.com/ap/ITCI. Advertisement. Sign up for the Daily Brief. Our free, fast, and fun briefing on the ...The stock of Intra-Cellular Therapies Inc (ITCI) has gone up by 5.10% for the week, with a -1.20% drop in the past month and a -13.62% drop in the past quarter. The volatility ratio for the week is 5.20%, and the volatility levels for the past 30 days are 3.88% for ITCI. The simple moving average for the last 20 days is -0.20% for ITCI stock ...Intra-Cellular Therapies Inc Stock , ITCI 58.90 -0.36 -0.61% After-market 06:22:19 PM EDT 11/22/2023 NAS Add to watchlist 59.26 +0.73 +1.25% Official Close …Mar 1, 2023 · Intra-Cellular (ITCI) delivered earnings and revenue surprises of 27.42% and 5.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? Stock itci

Mar 28, 2023 · The stock is down more than 12% over the past 12 months but up more than 2% so far in 2023. ... (ITCI) Q3 2021 Earnings Call Transcript. Why Intra-Cellular Therapies Was Weak This Week. . Stock itci

stock itci

NEW YORK, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, …18 thg 10, 2023 ... The ITCI gives a comprehensive overview of how developed countries' tax ... shares of stock.[74] These types of taxes increase the cost of ...Current. -$0.35. 1 Month Ago. -$0.41. 3 Months Ago. -$0.41. Intra-Cellular Therapies Inc. analyst estimates, including ITCI earnings per share estimates and analyst recommendations.ITCI - place your bets With a huge upcoming catalyst - CAPLYTA PDUFA due December 17th, 2021, it will make or break this stock - with an approval from the FDA, I expect pt of around 57, with possibility to hit all-time high within a year from CAPLYTA launch.Dec 1, 2023 · Earnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($1.68) to ($0.80) per share. Intra-Cellular Therapies has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 6th, 2024 based off prior year's report dates. Read More. Have the markets turned the corner? Maybe not – but maybe so, at least for the short term. Despite rising inflation in the States, and Russia’s continuing war against Ukraine, high prices for ...IntraCellular Therapies (ITCI) Quote Overview » More Research » IntraCellular Therapies (ITCI) Full Company Report Better trading starts here. Company SummaryIntra-Cellular Therapies Inc (ITCI) Intra-Cellular Therapies is a biopharmaceutical company focused on the discovery, clinical development and commercialization of small molecule drugs that address medical needs mainly in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system.Thank you for your interest in Intra-Cellular Therapies. For more information or to apply to our open positions, please visit our job postings on LinkedIn or send your resume to hr@ itci-inc.com. For Regional Business Manager (field sales leadership) or Neuroscience Sales Specialist roles, please visit the postings our field sales staffing ...The latest Intra-Cellular Therapies stock prices, stock quotes, news, and ITCI history to help you invest and trade smarter.Intra-Cellular: Q1 Earnings Snapshot. NEW YORK (AP) — NEW YORK (AP) — Intra-Cellular Therapies Inc. (ITCI) on Thursday reported a loss of $44.1 million in its first quarter. The New York-based company said it had a loss of 46 cents per share. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by ...Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting ...52 Week High. $67.05. 52 Week Low. $42.01. Data Provided by Refinitiv. Minimum 15 minutes delayed. The Investor Relations website contains information about Intra-Cellular Therapies Inc.'s business for stockholders, potential investors, and financial analysts. Nov. 08. CI. RBC Trims Price Target on Intra-Cellular Therapies to $76 From $77, Keeps Outperform Rating. Nov. 03. MT. Earnings Flash (ITCI) INTRA-CELLULAR THERAPIES Reports Q3 Revenue $126.2M. Nov. 02. MT. Transcript : Intra-Cellular Therapies, Inc., Q3 2023 Earnings Call, Nov 02, 2023.ITCI - Free Report) shares were up 2% on May 5, after the company reported better-than-expected first-quarter 2023 results on May 4. ITCI incurred a loss of 46 cents per share in the reported ...redhotace. 2. 7/7/2023 11:45:09 PM. 447. Needham raises PT to $73 From $70, Keeps Buy Rating. GN. redhotace.Nov 30, 2023 · 8 Wall Street analysts have issued 1-year target prices for Intra-Cellular Therapies' stock. Their ITCI share price targets range from $62.00 to $101.00. On average, they predict the company's stock price to reach $78.67 in the next year. This suggests a possible upside of 28.2% from the stock's current price. home / stock / itci / itci news. RSS . ITCI ITCI Quote ITCI Short ITCI News ITCI Articles ITCI Message Board. February, 24 2021 07:30 AM ... Feb. 24, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ...04:20 PM ET 03/28/2023. Intra-Cellular Therapies ( ITCI) said Tuesday that its depression treatment succeeded in a key study, and ITCI stock broke definitively above its 200-day line for the first ...Intra-Cellular Therapies Inc Stock , ITCI 58.90 -0.36 -0.61% After-market 06:22:19 PM EDT 11/22/2023 NAS Add to watchlist 59.26 +0.73 +1.25% Official Close …Intra-Cellular Therapies ( NASDAQ: ITCI) stock traded much higher recently after it had obtained FDA approval for its drug CAPLYTA (lumateperone) for the treatment of adults with bipolar ...Intra-Cellular Therapies Inc (ITCI) Intra-Cellular Therapies is a biopharmaceutical company focused on the discovery, clinical development and commercialization of small molecule drugs that address medical needs mainly in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system.On November 2, 2023, Intra-Cellular Therapies Inc (ITCI) stock had a median target price of $76.00, according to 13 analysts offering 12-month price forecasts. The high estimate for the stock was $100.00, while the low estimate was $59.00. The consensus among 14 investment analysts was to buy stock in Intra-Cellular Therapies Inc.Intra-Cellular (ITCI) delivered earnings and revenue surprises of 33.72% and 10.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Shares of ITCI responded in kind, rallying 16% in the subsequent trading session and ultimately 40% higher to an all-time high of $67.05 in June 2023, suggesting …Chg %. Market Cap. MediciNova Inc. -2.63%. $90.74M. ITCI | Complete Intra-Cellular Therapies Inc. stock news by MarketWatch. View real-time stock prices and stock …Nov 27, 2022 · Headquartered in Chelmsford, Massachusetts, Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is a sample exploration and management solutions provider for the life science market. On November 23, 2022 ... A high-level overview of Intra-Cellular Therapies, Inc. (ITCI) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Stock control is important because it prevents retailers from running out of products, according to the Houston Chronicle. Stock control also helps retailers keep track of goods that may have been lost or stolen.Intra-Cellular Therapies had revenue of $420.14M in the twelve months ending September 30, 2023, with 123.34% growth year-over-year. Revenue in the quarter ending September 30, 2023 was $126.17M with 75.56% year-over-year growth. In the year 2022, Intra-Cellular Therapies had annual revenue of $250.31M with 198.69% growth.May 4, 2023 · Intra-Cellular (ITCI) delivered earnings and revenue surprises of 26.98% and 3.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? Intra-Cellular Therapies ( NASDAQ: ITCI) stock traded much higher recently after it had obtained FDA approval for its drug CAPLYTA (lumateperone) for the treatment of adults with bipolar ...Mar 1, 2023 · Intra-Cellular (ITCI) delivered earnings and revenue surprises of 27.42% and 5.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? Find the latest Intra-Cellular Therapies, Inc. (ITCI) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.As of April 23, 2023, the average one-year price target for Intra-Cellular Therapies is 77.93. The forecasts range from a low of 56.56 to a high of $102.90. The average price target represents an ...Track Intra-Cellular Therapies Inc (ITCI) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors A high-level overview of Intra-Cellular Therapies, Inc. (ITCI) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the 2023 Cantor Fitzgerald Global Healthcare Conference on Wednesday, …ITCI - Intra-Cellular Therapies Inc Stock Price Quote - NASDAQ | Morningstar Intra-Cellular Therapies Inc ITCI Morningstar Rating | Rating as of Sep 7, 2023 Quote Chart Stock Analysis News...ITCI - Free Report) shares were up 2% on May 5, after the company reported better-than-expected first-quarter 2023 results on May 4. ITCI incurred a loss of 46 cents per share in the reported ...TimesSquare Capital highlighted stocks like Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) in its Q3 2022 investor letter. Headquartered in New York, New York, Intra-Cellular Therapies, Inc ...The company increased its Caplyta net product sales in the range of $445-$465 million (previously $430-$455 million) for the full-year 2023. Intra-Cellular, however, maintained its full-year 2023 ...itci The Nasdaq Global Select Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing ...Have the markets turned the corner? Maybe not – but maybe so, at least for the short term. Despite rising inflation in the States, and Russia’s continuing war against Ukraine, high prices for ...Intra-Cellular Therapies (ITCI) Stock Forecast, Price Targets ...Intra-Cellular (ITCI) Q2 Earnings & Sales Top, '23 View Raised. 08/04/23-7:40AM EST Zacks. Price is a widely used stock evaluation measure. Find the latest Price for IntraCellular Therapies (ITCI)With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.Insider Sell: Sharon Mates Sells 100,000 Shares of Intra-Cellular Therapies Inc. On September 19, 2023, Sharon Mates, Chairman, President & CEO of Intra-Cellular Therapies Inc (NASDAQ:ITCI), sold ... NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, …. Corning glass ticker